Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Ross, D. Griffith (1989)
The Clinical Presentation of PhaeochromocytomQJM: An International Journal of Medicine, 71
G. Eisenhofer, S. Bornstein, F. Brouwers, N. Cheung, P. Dahia, R. Krijger, T. Giordano, L. Greene, D. Goldstein, H. Lehnert, W. Manger, J. Maris, H. Neumann, K. Pacak, B. Shulkin, David Smith, A. Tischler, W. Young (2004)
Malignant pheochromocytoma: current status and initiatives for future progress.Endocrine-related cancer, 11 3
HM Brown, RA Komorowski, SD Wilson, MJ Demeure, YR Zhu (1999)
Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behaviorCancer, 86
Martha Clarke, Robert Weyant, Charles Watson, Sally Carty (1998)
Prognostic markers in pheochromocytoma.Human pathology, 29 5
LD Thompson, WF Young, A Kawashima, P Komminoth, AS Tischler (2004)
WHO classification of tumours: pathology and genetics—tumours of endocrine organs
H Lehnert, J Mundschenk, K Hahn (2004)
Malignant pheochromocytomaFront Hormon Res, 31
H. Brown, R. Komorowski, Stuart Wilson, M. Demeure, Yong‐ran Zhu (1999)
Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferationCancer, 86
Elisabeth Elder, Dawei Xu, A. Höög, U. Enberg, M. Hou, P. Pisa, A. Gruber, C. Larsson, M. Bäckdahl (2003)
KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and ParagangliomaModern Pathology, 16
L. Thompson (2002)
Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 CasesThe American Journal of Surgical Pathology, 26
L. Medeiros, B. Wolf, K. Balogh, M. Federman (1985)
Adrenal pheochromocytoma: a clinicopathologic review of 60 cases.Human pathology, 16 6
A. Khorram‐Manesh, H. Ahlman, O. Nilsson, P. Friberg, A. Odén, G. Stenström, G. Hansson, O. Stenquist, B. Wängberg, L. Tisell, S. Jansson (2005)
Long‐term outcome of a large series of patients surgically treated for pheochromocytomaJournal of Internal Medicine, 258
A. Grossman, K. Pacak, A. Sawka, J. Lenders, Debra Harlander, R. Peaston, R. Reznek, J. Sisson, G. Eisenhofer (2006)
Biochemical Diagnosis and Localization of PheochromocytomaAnnals of the New York Academy of Sciences, 1073
B. Glodny, G. Winde, R. Herwig, Antje Meier, C. Kühle, S. Cromme, H. Vetter (2001)
Clinical differences between benign and malignant pheochromocytomas.Endocrine journal, 48 2
A Grossman, K Pacak, A Sawka, JW Lenders, D Harlander, RT Peaston (2006)
Biochemical diagnosis and localization of phaeochromocytoma. Can we reach a consensus?Ann New York Acad Sci, 1073
Y. Anouar, L. Yon, J. Guillemot, E. Thouennon, L. Barbier, A. Gimenez-Roqueplo, J. Bertherat, H. Lefebvre, M. Klein, M. Mureşan, E. Grouzmann, P. Plouin, H. Vaudry, A. Elkahloun (2006)
Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytoma Using Peptide Marker Immunoassay and Gene Expression Profiling ApproachesAnnals of the New York Academy of Sciences, 1073
E. Achilles, B. Padberg, K. Holl, G. Klöppel, S. Schröder (1991)
Immunocytochemistry of paragangliomas—value of staining for S‐100 protein and glial fibrillary acid protein in diagnosis and prognosisHistopathology, 18
R. Linnoila, R. Linnoila, H. Keiser, H. Keiser, S. Steinberg, S. Steinberg, E. Lack, E. Lack (1990)
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features.Human pathology, 21 11
K. Pacak, G. Eisenhofer, H. Ahlman, S. Bornstein, A. Gimenez-Roqueplo, A. Grossman, N. Kimura, M. Mannelli, A. McNicol, A. Tischler (2007)
Pheochromocytoma: recommendations for clinical practice from the First International SymposiumNature Clinical Practice Endocrinology &Metabolism, 3
M. Fassnacht, M. Kreissl, D. Weismann, B. Allolio (2009)
New targets and therapeutic approaches for endocrine malignancies.Pharmacology & therapeutics, 123 1
N. Kimura, Toshiya Watanabe, T. Noshiro, S. Shizawa, Y. Miura (2005)
Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumorsEndocrine Pathology, 16
V. Strong, T. Kennedy, H. Al-Ahmadie, Laura Tang, J. Coleman, Y. Fong, M. Brennan, R. Ghossein (2008)
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.Surgery, 143 6
I. Ilias, K. Pacak (2008)
A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.Nuclear medicine and biology, 35 Suppl 1
K. Pacak, J. Lenders, G. Eisenhofer (2008)
Clinical Presentation of Pheochromocytoma
H. Neumann, B. Bausch, S. McWhinney, B. Bender, O. Gimm, G. Franke, J. Schipper, J. Klisch, C. Altehoefer, K. Zerres, A. Januszewicz, C. Eng, Wendy Smith, Robin Munk, T. Manz, S. Glaesker, T. Apel, M. Treier, M. Reineke, M. Walz, C. Hoang‐Vu, M. Brauckhoff, A. Klein-Franke, P. Klose, H. Schmidt, M. Maier-Woelfle, M. Peczkowska, Cesary Szmigielski (2002)
Germ-line mutations in nonsyndromic pheochromocytoma.The New England journal of medicine, 346 19
Jennifer Bryant, J. Farmer, L. Kessler, R. Townsend, K. Nathanson (2003)
Pheochromocytoma: the expanding genetic differential diagnosis.Journal of the National Cancer Institute, 95 16
EL Bravo, RW Gifford (1984)
Pheochromocytoma: diagnosis, localization and managementNew Engl J Med, 311
E. Harst, H. Bruining, H. Bonjer, F. Ham, W. Dinjens, S. Lamberts, W. Herder, J. Koper, T. Stijnen, C. Proye, M. Lecomte‐Houcke, F. Bosman, R. Krijger (2000)
Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?The Journal of Pathology, 191
R Zarnegar, E Kekebew, QY Duh, OH Clark (2006)
Malignant pheochromocytomaSurg Oncol Clin N Am, 15
EE Lack (1997)
Tumours of the adrenal gland and extra-adrenal paraganglia
S. Tavangar, A. Shojaee, Hedieh Tabriz, V. Haghpanah, B. Larijani, R. Heshmat, A. Lashkari, S. Azimi (2010)
Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.Pathology, research and practice, 206 5
G. Kaltsas, G. Besser, A. Grossman (2004)
The diagnosis and medical management of advanced neuroendocrine tumors.Endocrine reviews, 25 3
P. Unger, K. Hoffman, D. Pertsemlidis, S. Thung, D. Wolfe, M. Kaneko (1991)
S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas.Archives of pathology & laboratory medicine, 115 5
David Wu, A. Tischler, R. Lloyd, R. DeLellis, R. Krijger, F. Nederveen, V. Nosé (2009)
Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled ScoreThe American Journal of Surgical Pathology, 33
JW Lenders, G Eisenhofer, M Mannelli, K Pacak (2005)
PheochromocytomaLancet, 366
E. Bravo, R. Gifford (1984)
Current concepts. Pheochromocytoma: diagnosis, localization and management.The New England journal of medicine, 311 20
H. John, W. Ziegler, D. Hauri, Peter Jaeger (1999)
Pheochromocytomas: can malignant potential be predicted?Urology, 53 4
Langenbecks Arch Surg (2012) 397:239–246 DOI 10.1007/s00423-011-0850-3 ORIGINAL ARTICLE Pierre de Wailly & Luigi Oragano & Francois Radé & Anthony Beaulieu & Vincent Arnault & Pierre Levillain & Jean Louis Kraimps Received: 1 June 2011 /Accepted: 8 September 2011 /Published online: 9 November 2011 Springer-Verlag 2011 Abstract directly correlated to presence of TN (p<0.005) and Purpose The pathological diagnosis of malignancy in malignancy (G1 14.1%, G2 1.8%, G3 2.6%; p<0.001). pheochromocytomas remains a controversial issue. Accord- All G1 had a Ki-67 index >4%, although one G3 presented ing to the WHO, malignancy is defined in the presence of an 11% Ki-67 index. There was an inverse statistically metastasis. Multiparameter scoring systems such as PASS significant correlation between the three groups in staining (Pheochromocytoma of Adrenal gland Scaled Score) have using pS100 (p<0.01). been used but remain controversial. The aim of this study Conclusions Size and weight of the pheochromocytoma are was to search for new immunohistologic elements allowing directly related to PASS and malignancy. The presence of determination of pheochromocytoma malignancy. tumour necrosis, Ki-67 index >4% and pS100 absence Methods Among 53 patients operated for pheochromocy- impose a close histopathological evaluation and follow-up toma between 1993 and 2009, we
Langenbeck's Archives of Surgery – Springer Journals
Published: Nov 9, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.